Please login to the form below
Amicus
This page shows the latest Amicus news and features for those working in and with pharma, biotech and healthcare.
Amicus forms gene therapy manufacturing partnership with Catalent
The agreement will also see the development of an Adeno-Associated Virus (AAV) manufacturing platform, supporting the manufacturing of Amicus’ preclinical gene therapy programmes. ... capabilities. Thermo Fisher will supply Amicus with immediate access
Latest news
-
Orphan drugs from Biogen and Amicus win UK Prix Galien
New medical technology category added for the first time. Amicus’ Galafold and Biogen’s Spinraza have won the two top prizes at the UK Prix Galien, the biennial awards which recognise ... Amicus receive their award from health minister Lord
-
Daily Brief: Orchard raises $150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval
Amicus’s Galafold gains FDA approval, set to rival Fabrayzme. Amicus Therapeutics has received FDA approval for Galafold, the first oral therapy for the rare Fabry disease.
-
Orphan drugs dominate UK Prix Galien shortlist, medtech debuts
This year, the judges concluded that just two entrants were worthy of being shortlisted for the Innovative Product Award; Sanofi (Dupixent) and Amicus (Galafold). ... Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold),
-
Lucid picks up rare disease and orphan drugs trophy at PMEA 2017
Narrowly missing first place, but still achieving a highly commended status on the night was Amicus Therapeutics UK for its work on rare diseases. ... Judges said: “Amicus did a very good job for a small outfit in the start-up phase and they showed an
-
Amicus Therapeutics launches Fabry treatment Galafold in Italy
John Crowley, Amicus chairman and CEO, said: "The commercial launch of Galafold in Italy is a significant milestone for the Fabry community. ... Amicus’ therapy is a first-in-class chaperone therapy and works by stabilising the body's own
More from news
Approximately 8 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
including Shire/Takeda, Actelion/J&J, Sanofi Genzyme, Alexion, Amicus, BioMarin, Sarepta and Vertex.
-
Pharma deals in August 2015
Acquisition of remaining rights. 1034. Scioderm. Amicus. Galafold [migalastat] for Fabry's disease.
-
Pharma deals during November 2013
Secondly, Amicus announced the purchase of Callidus Biopharma for $15m in stock and up to $115m in milestones. ... The deal gives Amicus access to Callidus' late-stage enzyme replacement therapy for Pompe disease.
-
Deal Watch table for November 2013
152. Calidus / Amicus. Acquisition. Purchase of Callidus' late-stage enzyme replacement therapy for Pompe disease.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Dr Andrew Mulberg moves from FDA to Amicus Therapeutics
He becomes vice president of regulatory strategy. US biotechnology firm Amicus Therapeutics has appointed Dr Andrew Mulberg as its vice president of regulatory strategy. ... Dr Jay Barth, chief medical officer at Amicus, said: “I am very pleased to
-
Glenn Sblendorio to retire as president of The Medicines Company
He currently serves as a director at Amicus Therapeutics, Intercept Pharmaceuticals and Ophthotech Corporation.
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
